Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review

Hepatic dysfunction, in the absence of liver metastases, occurs in 10–15% of renal cell carcinoma (RCC) patients, while immune hepatitis due to anti-CTLA4 and anti-PD1 administration affects about 3–9% and 0.7–1.8% of treated patients, respectively. Liver toxicity following combination therapy (anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Case Rep Intern Med
Autors principals: Denaro, Nerina, Garrone, Ornella, Occelli, Marcella, Fea, Elena, Granetto, Cristina, Merlano, Marco Carlo, Numico, Gianmauro
Format: Artigo
Idioma:Inglês
Publicat: SMC Media Srl 2021
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8276930/
https://ncbi.nlm.nih.gov/pubmed/34268267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12890/2021_002639
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars